KEVIN P STARR
CIK 1192603 · last filed 2023-06-16
KEVIN P STARR is a corporate insider who has filed 80 SEC Form 4 insider transactions across 17 companies since 2007. The most recent filing, for SAGE, was dated Jun 16, 2023. Across all open-market trades the lifetime net is −$119.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $604.3M across reported positions. 67 SEC filings were submitted jointly with ROBERT I TEPPER.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$604.26M
17
80
-$119.26M
Filer Profile
3RD FLOOR
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Sage Therapeutics, Inc. (SAGE) Delisted | Director | 320,659 | $8.68 | $2.78M | -$35.52M | 24 | 2023-06-16 |
| Jounce Therapeutics, Inc. (JNCE) Delisted | 10%+ Owner | 3,265,434 | $1.88 | $6.14M | $0 | 1 | 2021-06-14 |
| NRIX | 10%+ Owner | 4,553,898 | $25.10 | $114.30M | $0 | 1 | 2021-02-08 |
| RVMD | 10%+ Owner | 1,909,317 | $203.77 | $389.06M | $0 | 1 | 2020-02-18 |
| Neon Therapeutics, Inc. (NTGN) Delisted | 10%+ Owner | 9,741,636 | — | — | $0 | 1 | 2018-07-03 |
| MyoKardia, Inc. (MYOK) Delisted | Director | 1,109,848 | — | — | -$71.43M | 12 | 2018-03-07 |
| Allena Pharmaceuticals, Inc. (ALNA) Delisted | 10%+ Owner | 2,575,964 | $0.07 | $193.2K | $15.05M | 1 | 2017-11-06 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | Director | 1,563,693 | $68.49 | $107.10M | -$1.74M | 5 | 2017-06-16 |
| ALNY | Director | 25,000 | $248.68 | $6.22M | -$16.06M | 14 | 2017-06-06 |
| CTMX | 10%+ Owner | 5,201,767 | $3.29 | $17.11M | -$463.8K | 3 | 2017-04-14 |
| Blueprint Medicines Corp (BPMC) Delisted | 10%+ Owner | 5,453,753 | $129.46 | $706.04M | -$3.00M | 3 | 2016-12-21 |
| EDIT | 10%+ Owner | 3,906,176 | $2.70 | $10.55M | -$93.7K | 1 | 2016-09-07 |
| VYGR | 10%+ Owner | 11,061,176 | $3.19 | $35.29M | $0 | 1 | 2015-11-18 |
| Larimar Therapeutics, Inc. (ZFGN) Delisted | Director | 70,541 | — | — | -$6.00M | 6 | 2015-09-25 |
| Foundation Medicine, Inc. (FMI) Delisted | 10%+ Owner | 0 | — | — | $0 | 1 | 2015-05-15 |
| AGIO | Director | 944,581 | $33.60 | $31.74M | $0 | 3 | 2015-02-19 |
| HUMAN GENOME SCIENCES INC (HGSI) Delisted | Director | 695 | — | — | $0 | 2 | 2007-07-12 |
Recent Filings
80 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-06-16 | Sage Therapeutics, Inc. (SAGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-17 | Sage Therapeutics, Inc. (SAGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-17 | Sage Therapeutics, Inc. (SAGE) Delisted | Buy (P) | +17,842 | $1000.0K | EDGAR |
| 2021-06-14 | Jounce Therapeutics, Inc. (JNCE) Delisted | Other (J) | −9,000,000 | $0 | EDGAR |
| 2021-06-11 | Sage Therapeutics, Inc. (SAGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-02-08 | NRIX | Other (J) | −5,485,296 | $0 | EDGAR |
| 2020-06-11 | Sage Therapeutics, Inc. (SAGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-02-18 | RVMD | Conv (C) | +94,701,078 | $0 | EDGAR |
| 2019-06-06 | Sage Therapeutics, Inc. (SAGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-02-14 | Sage Therapeutics, Inc. (SAGE) Delisted | Sell (S) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.